Roth Capital Predicts Reduced Earnings for Journey Medical

Journey Medical Co. (NASDAQ:DERM) – Investment analysts at Roth Capital lowered their Q1 2025 earnings per share estimates for shares of Journey Medical in a research report issued on Thursday, March 27th. Roth Capital analyst J. Wittes now expects that the company will earn ($0.19) per share for the quarter, down from their previous estimate of ($0.05). The consensus estimate for Journey Medical’s current full-year earnings is ($1.02) per share. Roth Capital also issued estimates for Journey Medical’s Q2 2025 earnings at ($0.02) EPS, FY2025 earnings at $0.05 EPS, FY2026 earnings at $2.18 EPS, FY2027 earnings at $3.32 EPS and FY2028 earnings at $5.18 EPS.

Separately, Alliance Global Partners reiterated a “buy” rating on shares of Journey Medical in a research note on Thursday, March 27th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $9.67.

Journey Medical Trading Up 1.2 %

NASDAQ:DERM opened at $5.97 on Monday. The stock has a fifty day moving average price of $5.18 and a 200 day moving average price of $5.18. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 1.81. Journey Medical has a 12-month low of $3.20 and a 12-month high of $6.89. The firm has a market cap of $124.71 million, a PE ratio of -6.35 and a beta of 0.97.

Journey Medical (NASDAQ:DERM) last posted its quarterly earnings results on Wednesday, March 26th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.22) by $0.30. The business had revenue of $14.30 million during the quarter, compared to the consensus estimate of $14.21 million. Journey Medical had a negative net margin of 31.74% and a negative return on equity of 132.10%.

Insider Transactions at Journey Medical

In related news, CEO Claude Maraoui sold 49,271 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $5.01, for a total value of $246,847.71. Following the transaction, the chief executive officer now owns 2,003,147 shares of the company’s stock, valued at $10,035,766.47. This represents a 2.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In the last three months, insiders sold 105,831 shares of company stock valued at $536,622. Insiders own 13.16% of the company’s stock.

Institutional Trading of Journey Medical

A number of institutional investors have recently bought and sold shares of DERM. Cetera Investment Advisers raised its position in shares of Journey Medical by 21.8% during the 4th quarter. Cetera Investment Advisers now owns 13,839 shares of the company’s stock worth $54,000 after acquiring an additional 2,478 shares in the last quarter. Kovitz Investment Group Partners LLC acquired a new stake in Journey Medical during the third quarter worth approximately $66,000. Dimensional Fund Advisors LP purchased a new stake in shares of Journey Medical during the 4th quarter worth approximately $80,000. Citadel Advisors LLC acquired a new position in shares of Journey Medical in the 4th quarter valued at $174,000. Finally, Geode Capital Management LLC grew its position in shares of Journey Medical by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 108,435 shares of the company’s stock valued at $613,000 after buying an additional 12,882 shares during the last quarter. 7.25% of the stock is owned by hedge funds and other institutional investors.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.